Putting More Weight on Obesity Trials in Heart Failure.

Authors :: Harrington J
Sattar N
Felker GM
Januzzi JL
Lam CSP
Pagidipati NJ
Pandey A
Van Spall HGC
McGuire DK
Source :: Current heart failure reports [Curr Heart Fail Rep] 2024 Jun; Vol. 21 (3), pp. 194-202. Date of Electronic Publication: 2024 Apr 15.
Publication Year :: 2024
Abstract: Purpose of Review: To review ongoing and planned clinical trials of weight loss among individuals with or at high risk of heart failure.<br />Recent Findings: Intentional weight loss via semaglutide among persons with heart failure and preserved ejection fraction and obesity significantly improves weight loss and health status as assessed by the KCCQ-CSS score and is associated with improvements in 6-min walk test. Ongoing and planned trials will explore the role of intentional weight loss with treatments such as semaglutide or tirzepatide for individuals with heart failure across the entire ejection fraction spectrum.<br /> (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)